Fondazione IRCCS Policlinico San Matteo
Fondazione IRCCS Policlinico San Matteo is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A single arm, open label, clinical study of cryopreserved autologous CD34+ cells transduced with lentiviral vector containing human ARSA cDNA, for the treatment of early onset Metachromatic Leukodystrophy (MLD)
Sponsor Orchard Therapeutics (Europe) Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available5 trial-level findings · Read insights
- The study was authorized and conducted at a single clinical site in Italy, and all treated subjects received OTL-200 in Italy.
- The planned sample size was based on feasibility in rare MLD rather than statistical considerations.
- Protocol version 6 expanded eligibility to permit enrollment and treatment of early-juvenile MLD at early symptomatic stages before rapid disease progression.
- Protocol version 7 specified arrangements for remote follow-up visits, including assessments by local healthcare professionals or teleconferencing.
- Protocol version 8 reduced required study long-term follow-up to a minimum of 5 years and allowed rollover to a 15-year post-treatment follow-up study.
These findings describe the trial, not the service provider’s performance or responsibility.
A phase I/II open label study to assess safety, feasibility and efficacy of ex vivo expanded, autologous haematopoietic stem and progenitor cell populations that contain CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA in children with autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene.
Sponsor Fondazione Telethon Ets
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open-label phase 1/2 study to evaluate the safety, biological response and efficacy of a single dose of Temferon (autologous CD34+-enriched hematopoietic stem and progenitors cells genetically modified with human Interferon-α2) in patients with metastatic renal cell carcinoma
Sponsor Genenta Science S.p.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase I/II clinical trial of hematopoietic stem cell gene therapy for the treatment of Metachromatic Leukodystrophy
Sponsor Orchard Therapeutics (Europe) Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open label, non-randomized trial to evaluate the safety and efficacy of a single infusion of OTL-200 in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)
Sponsor Orchard Therapeutics (Europe) Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Fondazione IRCCS Policlinico San Matteo?
The 2026-10-09 snapshot links Fondazione IRCCS Policlinico San Matteo to 5 distinct CTIS trials. Recorded services include Busulfan PK analysis, Laboratory services, Busulphaemia measurement, Therapeutic drug monitoring (PK), among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Fondazione IRCCS Policlinico San Matteo?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Metabolic Disorders, Neurology. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Fondazione IRCCS Policlinico San Matteo conducted?
The linked trials record locations in 1 country, including Italy. These are trial locations, not confirmed office locations or countries where Fondazione IRCCS Policlinico San Matteo delivered services.
What can this page tell me about Fondazione IRCCS Policlinico San Matteo's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Fondazione IRCCS Policlinico San Matteo. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Fondazione IRCCS Policlinico San Matteo